Fuse-binding protein 1 is a target of the EZH2 inhibitor GSK343, in osteosarcoma cells
Authors:
- 27 May 2016
- journal article
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 49 (2) , 623-628
Abstract
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publicationsKeywords
This publication has 41 references indexed in Scilit:
- Enhancer of zeste homolog 2 silencing inhibits tumor growth and lung metastasis in osteosarcomaScientific Reports, 2015
- EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human CancersPLOS ONE, 2013
- EZH2 Is Essential for Glioblastoma Cancer Stem Cell MaintenanceCancer Research, 2009
- Roles of the EZH2 histone methyltransferase in cancer epigeneticsMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2008
- Osteosarcoma Development and Stem Cell DifferentiationClinical Orthopaedics and Related Research, 2008
- Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancerNature Genetics, 2006
- EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cellsProceedings of the National Academy of Sciences, 2003
- Role of Histone H3 Lysine 27 Methylation in Polycomb-Group SilencingScience, 2002
- The polycomb group protein EZH2 is involved in progression of prostate cancerNature, 2002
- Drosophila Enhancer of Zeste/ESC Complexes Have a Histone H3 Methyltransferase Activity that Marks Chromosomal Polycomb SitesCell, 2002